The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Shilov Yu.E.

Mental Health Research Center

Baymeeva N.V.

Mental Health Research Center

Brusov O.S.

Mental Health Research Center

Oleĭchik I.V.

Mental Health Research Centre

Sizov S.V.

Mental Health Research Center

Tyurin I.A.

N.V. Sklifosovsky Research Institute of Emergency Medicine of Department of Health of Moscow

Cinnabarinic acid as a potential prognostic marker of schizophrenia

Authors:

Shilov Yu.E., Baymeeva N.V., Brusov O.S., Oleĭchik I.V., Sizov S.V., Tyurin I.A.

More about the authors

Read: 1278 times


To cite this article:

Shilov YuE, Baymeeva NV, Brusov OS, Oleĭchik IV, Sizov SV, Tyurin IA. Cinnabarinic acid as a potential prognostic marker of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(12):138‑142. (In Russ.)
https://doi.org/10.17116/jnevro2022122121138

References:

  1. Muneer A. Kynurenine pathway of tryptophan metabolism in neuropsychiatric disorders: pathophysiologic and therapeutic considerations. Clin Psychopharmacol Neurosci. 2020;18(4):507-526.  https://doi.org/10.9758/cpn.2020.18.4.507
  2. de Carvalho LP, Bochet P, Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochemistry Int. 1996;28(4):445-452.  https://doi.org/10.1016/0197-0186(95)00091-7
  3. Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2017;112(Pt B):297-306.  https://doi.org/10.1016/j.neuropharm.2016.05.020
  4. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13(7):465-477.  https://doi.org/10.1038/nrn3257
  5. Wonodi I, Stine OC, Sathyasaikumar KV, et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry. 2011;68(7):665-674.  https://doi.org/10.1001/archgenpsychiatry.2011.71
  6. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4-15.  https://doi.org/10.1038/npp.2011.181
  7. Plitman E, Iwata Y, Caravaggio F, et al. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2017;43(4):764-777.  https://doi.org/10.1093/schbul/sbw221
  8. Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75-83.  https://doi.org/10.1093/schbul/sbx035
  9. Lowe MM, Mold JE, Kanwar B, et al. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One. 2014;9(2):e87877. Published 2014 Feb 3.  https://doi.org/10.1371/journal.pone.0087877
  10. Pasceri R, Siegel D, Ross D, Moody CJ. Aminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin A. J Med Chem. 2013;56(8):3310-3317. https://doi.org/10.1021/jm400049z
  11. Fazio F, Lionetto L, Molinaro G, et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol. 2012;81(5):643-656.  https://doi.org/10.1124/mol.111.074765
  12. Nicoletti F, Orlando R, Di Menna L, et al. Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia. Front Psychiatry. 2019;10:49. Published 2019 Feb 14.  https://doi.org/10.3389/fpsyt.2019.00049
  13. Maksymetz J, Moran SP, Conn PJ. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain. 2017;10(1):15. Published 2017 Apr 26.  https://doi.org/10.1186/s13041-017-0293-z
  14. Fazio F, Zappulla C, Notartomaso S, et al. Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice. Neuropharmacology. 2014;81:237-243.  https://doi.org/10.1016/j.neuropharm.2014.02.011
  15. Fraguas D, Díaz-Caneja CM, Ayora M, et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophr Bull. 2019;45(4):742-751.  https://doi.org/10.1093/schbul/sby125
  16. Orlovska-Waast S, Köhler-Forsberg O, Brix SW, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis [published correction appears in Mol Psychiatry. 2019 Mar 12]. Mol Psychiatry. 2019;24(6):869-887.  https://doi.org/10.1038/s41380-018-0220-4
  17. Ulivieri M, Wierońska JM, Lionetto L, et al. The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia. Schizophr Bull. 2020;46(6):1471-1481. https://doi.org/10.1093/schbul/sbaa074

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.